Last reviewed · How we verify
Monovalent Frozen FluMist®
FluMist®, a monovalent frozen influenza vaccine marketed by MedImmune LLC, holds a distinct position in the flu vaccine market. The key composition patent for FluMist® is set to expire in 2028, providing a period of exclusivity that supports its competitive edge. The primary risk to FluMist® is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Monovalent Frozen FluMist® |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Assess the Safety of a New Influenza Vaccine (PHASE4)
- A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monovalent Frozen FluMist® CI brief — competitive landscape report
- Monovalent Frozen FluMist® updates RSS · CI watch RSS
- MedImmune LLC portfolio CI